MedTrace Logo

Clinical Study of Genakumab for Injection in Patients With Acute Gout

NCT05328531 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2025-02-27

No results posted yet for this study

Summary

To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout

Conditions

  • Acute Gout

Interventions

DRUG

Genakumab for Injection

150 mg/1ml/bottle

DRUG

Placebo for Genakumab for Injection

The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection

Sponsors & Collaborators

  • Huashan Hospital

    collaborator OTHER

  • Hainan General Hospital

    collaborator OTHER

  • Linyi People's Hospital

    collaborator OTHER

  • The Second Affiliated Hospital of Chongqing Medical University

    collaborator OTHER

  • Changhai Hospital

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • Shengjing Hospital

    collaborator OTHER

  • Affiliated Hospital of Nantong University

    collaborator OTHER

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hejian Zou · Huashan Hospital

  • Jing Zhang · Huashan Hospital of Fudan Univeisity

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-22
Primary Completion
2022-06-09
Completion
2022-06-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05328531 on ClinicalTrials.gov